Mammalian biomanufacturing

Published: 16-Jul-2024

Delivering consistent and scalable mammalian-derived products, Scorpius uses its American facilities to advance your drug from R&D to the clinic and beyond

Scorpius has ~5,400 sq. ft. of its contract biomanufacturing facility in San Antonio, Texas for mammalian cell culture and harvest and downstream processes operations.

The facility’s multi-modal design contains seven cGMP-compliant controlled cleanrooms that utilize single-use systems to allow for greater flexibility, enhanced sterility assurance, and faster processing times with increased productivity.

Scorpius can support monoclonal antibody production, bi- and tri-specific products, antibody drug conjugates, allogeneic cell therapy products, and insect cell line-derived products in this facility.

The mammalian leadership team has 100+ years of industry experience working with mammalian expression systems, including CHO, NS0, 3T3, and HEK293 cell lines. Scorpius also has experience working with tissue culture, including stem cell-derived products.

You may also like